Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.94 EUR 0.83%
Market Cap: 157m EUR
Have any thoughts about
Innate Pharma SA?
Write Note

EV/OCF
Enterprise Value to OCF

-8.2
Current
-6.5
Median
5.9
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-8.2
=
Enterprise Value
147.9m EUR
/
Operating Cash Flow
-18.1m EUR
All Countries
Close
Market Cap EV/OCF
FR
Innate Pharma SA
PAR:IPH
160.9m EUR -8.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -238 968.6
US
Abbvie Inc
NYSE:ABBV
310.2B USD 21.9
US
Amgen Inc
NASDAQ:AMGN
142B USD 26.1
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 11
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD -112.4
US
Epizyme Inc
F:EPE
94.1B EUR -471.2
AU
CSL Ltd
ASX:CSL
134.4B AUD 33.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD 16.5
US
Seagen Inc
F:SGT
39.3B EUR -73.7
NL
argenx SE
XBRU:ARGX
36B EUR -132
 
FR
Innate Pharma SA
PAR:IPH
Average EV/OCF: 21.9
Negative Multiple: -8.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -238 968.6
US
Abbvie Inc
NYSE:ABBV
21.9
US
Amgen Inc
NASDAQ:AMGN
26.1
US
Gilead Sciences Inc
NASDAQ:GILD
11
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -112.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.2
AU
CSL Ltd
ASX:CSL
33.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -73.7
NL
argenx SE
XBRU:ARGX
Negative Multiple: -132

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A

See Also

Discover More